Compare Digital Realty Trust, Inc. (DLR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Digital Realty Trust, Inc. trades at $176.26 (market cap $65.32B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Digital Realty Trust, Inc. pays a 2.77% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DLR | VRTX | |
|---|---|---|
Market Cap | $65.32B | $127.55B |
Volume | 2,563,950 | 1,487,944 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $557.96 |
52-Week Low | $147.93 | $407.37 |
Typical Hold Time | 94 Days | 120 Days |
Enterprise Value | $84.03B | $121.68B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLR trades at $180.47, down 2.26% today, with a bearish technical signal. The stock shows strong fundamentals: revenue grew to $6.11B in 2025, net income margin improved to 21.4%, and Q2 2026 EPS beat expectations. Analysts are overwhelmingly bullish with a $222.35 consensus target. Recent news highlights AI infrastructure expansion, including a partnership with Blackfuel and a new cable landing station in Los Angeles, driving positive sentiment.
Outlook is positive due to robust AI-driven demand and record leasing activity, but risks include high valuation (P/E 88.03) and significant capital expenditures. Net cash flow turned negative in 2025, and debt levels remain elevated. The stock offers growth potential from the AI boom, yet investors should weigh execution risks and macroeconomic sensitivity.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
